An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

September 9, 2013

Primary Completion Date

August 6, 2014

Study Completion Date

September 1, 2014

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

JNJ 49095397

JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.

DRUG

Placebo

Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.

Trial Locations (47)

Unknown

Phoenix

St Louis

Chapel Hill

Charlotte

Cincinnati

Spartanburg

Antwerp

Brussels

Genk

Kortrijk

Leuven

Calgary

Edmonton

Hamilton

Ottawa

Toronto

Montreal

Sainte-Foy

Sherbrooke

Prague

Berlin

Frankfurt

Großhansdorf

Hamburg

Lübeck

Mainz

Budapest

Farkasgyepü

Mosonmagyaróvár

Szikszó

Eindhoven

Groningen

Rotterdam

Sittard / Geleen

Zwolle

Bialystok

Lodz

Wroclaw

Bucharest

Barnaul

Moscow

Saint Petersburg

Bristol

Dundee

Edinburgh

Glasgow

London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter